Gracell Bio - Bathi resik saben saham sajrone 12 wulan pungkasan GRCL

Gracell (GRCL) - logo korporat

Gracell Biotechnologies (GRCL) is expanding its influence through innovative cryogenic logistics for CAR-T therapies. The 12-month EPS growth trend confirms the sustainability of the trajectory, with the current level sitting around 25.80. Financial security is guaranteed by a merger with a pharma behemoth, while technological progress is driven by leading experts in the field of gene editing.

gracellbio.com (GRCL): Bathi saben saham sajrone rolas wulan pungkasan saka 11.02.2024 nganti 20.02.2024

Rincian metrik keuangan lan pasar Gracell Biotechnologies (GRCL)

Pambiji fundamental perusahaan:GRCL Gracell Biotechnologies Inc.
Barang unggulan Gracell

Gracell Biotechnologies (GRCL) has been integrated into the structure of a global pharmaceutical behemoth to scale cell technologies. The dynamics of this merger directly impact the calculated earnings per share. This indicator measures the rolling annual EPS growth rate, bridging the gap between GAAP reporting and operating cash flow. It reveals fundamental resilience or signs of asset overheating. By analyzing the EPS YoY TTM growth value, an investor assesses the efficiency of the acquisition.